Vorasidenib
- Generic Name
- Vorasidenib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C14H13ClF6N6
- CAS Number
- 1644545-52-7
- Unique Ingredient Identifier
- 789Q85GA8P
- Associated Conditions
- -
- Associated Therapies
- -
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
- Conditions
- Interventions
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 45
- Registration Number
- NCT06478212
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Netherlands
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸University of California, San Francisco (UCSF) School of Medicine, San Francisco, California, United States
A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 16
- Registration Number
- NCT05674474
- Locations
- 🇺🇸
American Research Corporation, San Antonio, Texas, United States
Vorasidenib Expanded Access Program
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Servier
- Registration Number
- NCT05592743
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 72
- Registration Number
- NCT05484622
- Locations
- 🇺🇸
Northwestern University (Site: 840123), Chicago, Illinois, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Florida, Cleveland, Ohio, United States
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
- Conditions
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 331
- Registration Number
- NCT04164901
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.